Inactive Instrument

Amarin Corporation plc (ADR) Stock Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

Real-time Estimate Tradegate 15:59:59 2024-05-23 EDT
0.783 EUR 0.00% Intraday chart for Amarin Corporation plc (ADR)

Financials

Sales 2024 * 202M 187M 277M Sales 2025 * 215M 199M 295M Capitalization 358M 331M 492M
Net income 2024 * -70M -64.74M -96.08M Net income 2025 * -64M -59.19M -87.85M EV / Sales 2024 * 1.55 x
Net cash position 2024 * 43.92M 40.62M 60.28M Net cash position 2025 * 159M 147M 218M EV / Sales 2025 * 0.93 x
P/E ratio 2024 *
-4.94 x
P/E ratio 2025 *
-5.24 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares. CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amarin Corporation plc authorizes a Buyback Plan. CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
More news

Latest transcript on Amarin Corporation plc (ADR)

Managers TitleAgeSince
Chief Executive Officer 52 23-07-17
Director of Finance/CFO 52 22-06-19
Compliance Officer 55 11-14
Members of the board TitleAgeSince
Director/Board Member 45 23-02-27
Chairman 49 23-02-27
Director/Board Member 66 23-02-27
More insiders
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company